Inhibikase Therapeutics Inc

Several biotech stocks reached 52-week highs on July 24, 2026, driven by upcoming quarterly reports and regulatory milestones. Inhibikase Therapeutics hit $2.53 after its lead candidate IKT-001 received FDA Orphan Drug designation for pulmonary arterial hypertension, with a global Phase 3 trial underway. Jazz Pharmaceuticals reached $256.75, supported by 19% first-quarter revenue growth to $1.1 billion and progress with Zanidatamab in breast cancer studies. Halozyme Therapeutics climbed to $82.99 following a 42% year-over-year revenue increase to $376 million in the first quarter and full-year guidance of $1.71 billion to $1.81 billion. Corcept Therapeutics touched $97.63, with first-quarter revenue rising to $164 million from $157 million a year earlier, ahead of its July 29 earnings report. Liquidia Corporation hit $91.10, buoyed by $130 million in first-quarter YUTREPIA sales and a net income of $52 million.

Several biotech stocks reached 52-week highs on July 14, 2026, driven by capital-raising efforts and business expansions. The Oncology Institute hit $6.66 after repaying an $86 million convertible note and projecting full-year 2026 revenue of $630 million to $650 million. Inhibikase Therapeutics rose over 5% to $2.36 following a $50 million at-the-market share sale to fund its Phase 3 trial for pulmonary arterial hypertension drug IKT-001. Alto Neuroscience reached $28.85 after pricing a $100 million direct offering to advance its lead depression candidate ALTO-207 toward Phase 3. Elevance Health touched $434.38, supported by an estimated 2026 adjusted EPS of at least $26.75 and a consumer base of approximately 105 million. Privia Health Group climbed to $28.30, forecasting 2026 GAAP revenue of $2.35 billion to $2.45 billion, up from $2.12 billion in 2025.

Inhibikase Therapeutics has sold 25 million shares of common stock to RA Capital Management through its at-the-market facility, raising $50 million in gross proceeds. The new capital, combined with existing reserves, will fund operations through the topline data readout in Part B of its ongoing global Phase 3 IMPROVE-PAH study, pending full exercise of outstanding Series A and B warrants. The financing was executed under a shelf registration statement declared effective by the SEC in June 2025, with a prospectus supplement filed in December 2025. Inhibikase's lead candidate, IKT-001, is a prodrug of imatinib mesylate being developed for Pulmonary Arterial Hypertension, a progressive and life-threatening disease affecting about 50,000 Americans. The pivotal Phase 3 IMPROVE-PAH trial is enrolling patients across roughly 180 sites worldwide.